Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral difelikefalin for moderate-to-severe pruritus in advanced chronic kidney disease
MOH_2024-01-08_013167Phase 2Not yet recruiting
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Sep 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of difelikefalin in chronic kidney disease (CKD) (4 arms), sponsored by Cara Therapeutics, Inc. Primary endpoints: Pharmacokinetic profile of oral difelikefalin, Exposure-response relationship and 2 more. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
difelikefalin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on MOH_2024-01-08_013167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-08_013167.